NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Marqeta, Inc. (“Marqeta” or the “Company”) (NASDAQ:MQ) on behalf of Marqeta stockholders. Our investigation concerns whether Marqeta has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On November 4, 2024, Marqeta slashed its revenue growth forecast for the fourth quarter. The Company blamed “the heightened scrutiny of the banking environment and specific customer program changes” for its lowered expectations. Following this news, Marqeta stock dropped roughly 35% during trading the next day.
If you purchased or otherwise acquired Marqeta shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
- TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma - December 8, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 8, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 8, 2024